Lecture 44 Flashcards

1
Q

AD is the major cause of dementia

A

2:1 female:male

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Environmental risk factors of AD

A

Age

Low educational level

Reduced mental activity in late life

Reduced physical activity in late life

Risk for vascular disease

Head injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

AD pathophysiology

A

amyloid plaques and neurofibrillary tangles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Amyloid plaques

A

extracellular

consist of amyloid-B peptide (AB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Neurofibrillary tangles

A

intracellular

consist of hyperphosphorylated tau

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Progression of AD neuropathology

A

Neuropathology primarily affects areas of higher cognitive function:

entorhinal cortex (memory formation/consolidation)

hippocampus (memory formation/consolidation)

basal forebrain cholinergic systems (learning)

neocortex (memory, learning, cognition)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Amyloid plaques, neurofibrillary tangles, and synapse loss

A

Synapse loss results in reduced levels of neurotransmitters–especially acetylcholine, but also serotonin, norepinephrine, and dopamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which is the key pathogenic molecule: AB or tau?

A

Genetic evidence suggests a key role for AB:

Trisomy 21 is associated with an AD-like phenotype in the 4th decade of life, and the APP GENE IS LOCATED ON CHROMOSOME 21

Mutation in the gene encoding presenilin proteins involved in cleaving AB from APP are linked to early onset AD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Production of AB peptide from APP

A

AB peptide is released from the transmembrane amyloid precursor protein (APP) by the activity of B-secretase (BACE1) and y-secretase

Mutations in the APP gene favor cleavage by B- or y-secretase, resulting in the production of more AB42 relative to AB40

Mutations in the gene encoding presenilin-1 or presenilin-2 which are components of the y-secretase complex, alter APP cleave by y-secretase resulting in more production of AB42 than AB40

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Effects of AB aggregation on tau pathology

A

Kinase activation–> tau hyperphosphorylation–> neurofibrillary tangles–> disruption of cytoskeleton axonal trafficking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Neurofibrillary tangle formation results in cytoskeletal defects

A

In unhealthy areas where tangles have accumulated, the cytoskeletal tracks are disrupted and disorganized, resulting in defects in axonal transport that lead to synaptic dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Effects of AB aggregation on microglial activation

A

activated microglia release proinflammatory cytokines that cause neuroinflammation

activated microglia also release reactive nitrogen species and reactive oxygen species that cause oxidative stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Impact of ApoE genetics on AD risk

A

Individuals with 1 or 2 ApoE4 alleles have an increased risk of AD, whereas inheritance of the Apoe2 allele decreases the risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Summary of AD risk factors and pathogenic mechanisms

A

SLIDE 17

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Donepezil

A

specific, reversible inhibitor of acetylcholinesterase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Rivastigmine

A

inhibits acetylcholinesterase and butyrylcholinesterase

17
Q

Galantamine

A

selective, reversible inhibitor of acetylcholinesterase and enhance the action of acetylcholine on nicotinic receptors (increases ACH release from cholinergic neurons)

18
Q

Memantine

A

NMDA antagonist that blocks glutamatergic neurotransmission via a noncompetitive mechanism, reduces excitotoxicity

19
Q

Strategies for disease modifying therapy

A

AB generation (B- and y-secretase inhibitors)

AB aggregation (inositol, polyphenols, peptides)

AB clearance (vaccines, AB antibodies–aducanumab, lecanemab, donanemab: AB aggregate-specific antibodies

tau kinase inhibitors (lithium, valproate)

glutamate-mediated excitotoxicity (troriluzole, which induces expression of glial glutamate transporter GLT-1)

inflammation or oxidative stress (anti-inflammatory agents (NSAIDS, dietary antioxidants)

20
Q

Imaging

A

Florbetapir (18F)

Radiolabeled agents that binds to B-amyloid, visualized by PET scan

Radiolabeled agent specific for tau: 18F-Flortaucipir

21
Q

Vascular dementia

A

Impaired judgement or executive function is more common initial symptom than the memory loss characteristic of AD

Occurs as a result of brain injury associated with vascular disease or strole

22
Q

Dementia with Lewy bodies

A

combination of cognitive decline and parkinsonian symptoms

visual hallucinations core diagnostic feature

cortical lewy bodies

23
Q

Frontotemporal dementia

A

Disinhibited behavior, poor impulse control, antisocial behavior

Neuropathology is characterized by the presence of tau accumulations (Pick’s bodies)